Provided by Tiger Trade Technology Pte. Ltd.

Biomea Fusion, Inc.

1.52
+0.06004.11%
Post-market: 1.520.00000.00%19:59 EST
Volume:1.95M
Turnover:2.93M
Market Cap:107.47M
PE:-0.69
High:1.53
Open:1.52
Low:1.43
Close:1.46
52wk High:4.59
52wk Low:0.8719
Shares:70.70M
Float Shares:57.24M
Volume Ratio:1.48
T/O Rate:3.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2050
EPS(LYR):-3.8339
ROE:-209.00%
ROA:-75.23%
PB:6.88
PE(LYR):-0.40

Loading ...

Biomea Fusion initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
7 hours ago

Biomea Fusion Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Yesterday

Biomea Fusion Inc. Announces 2026 Strategy Focusing on Advancing Icovamenib and BMF-650 Clinical Programs, Initiating Phase II Trials in Type 2 Diabetes and Continuing Oral GLP-1 Candidate Development

Reuters
·
Jan 12

Director and Officer Rainer M. Erdtmann Acquires Common Shares of Biomea Fusion Inc

Reuters
·
Dec 16, 2025

Biomea Fusion Highlights Icovamenib Data at WCIRDC 2025

Reuters
·
Dec 10, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies

Reuters
·
Dec 06, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's Secret

Reuters
·
Dec 05, 2025

BUZZ-Biomea Fusion rises as diabetes drug shows promise

Reuters
·
Dec 05, 2025

Biomea Fusion Reports Durable Glycemic Improvements with Icovamenib in Type 2 Diabetes Trial

Reuters
·
Dec 05, 2025

Biomea Fusion Presents Covalent-111 Study Results at the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)

THOMSON REUTERS
·
Dec 05, 2025

Interim CEO Michael J.M. Hitchcock Reports Acquisition of Biomea Fusion Inc. Common Shares

Reuters
·
Dec 05, 2025

Biomea Fusion Inc. CEO and Director Rainer M. Erdtmann Reports Acquisition of Common Shares

Reuters
·
Dec 03, 2025

Biomea Fusion Unveils Positive Long-Term Icovamenib Data in Type 2 Diabetes at WCIRDC

Reuters
·
Dec 02, 2025

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)

THOMSON REUTERS
·
Dec 02, 2025

Biomea Fusion Grants Stock Options to New Employee Under 2023 Inducement Plan

Reuters
·
Dec 02, 2025

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 02, 2025

Biomea Fusion to Join Piper Sandler and Evercore Healthcare Investor Conferences

Reuters
·
Nov 24, 2025

JPMorgan Downgrades Biomea Fusion to Underweight From Neutral

MT Newswires Live
·
Nov 17, 2025

U.S. RESEARCH ROUNDUP- Applied Materials, Blackstone Mortgage, Brookdale Senior Living

Reuters
·
Nov 17, 2025

Biomea Fusion Inc : JP Morgan Cuts to Underweight From Neutral

THOMSON REUTERS
·
Nov 17, 2025